PUBLISHER: The Business Research Company | PRODUCT CODE: 1678196
PUBLISHER: The Business Research Company | PRODUCT CODE: 1678196
Osteoporosis drugs are medications designed to increase bone mineral density, reducing the risk of fractures. They are used both in the treatment and prevention of fractures, aiming to strengthen bones and prevent bone loss associated with osteoporosis.
The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.
The osteoporosis drugs market research report is one of a series of new reports from The Business Research Company that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12.33 billion in 2024 to $12.8 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to aging population, increased awareness and diagnosis, lifestyle factors, government initiatives and healthcare policies.
The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to continued aging population trends, advancements in treatment options, increased focus on men's bone health, patient education and empowerment, global health policies and insurance coverage. Major trends in the forecast period include personalized medicine approaches, exploration of combination therapies, focus on fracture prevention strategies, R&D investment in novel drug targets, collaborations for drug development.
An increase in the prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis is a bone condition characterized by a decrease in bone mineral density and mass or changes in bone quality and structure. Individuals with low calcium intake are at a higher risk of developing osteoporosis. These osteoporosis medications work to enhance bone mineral density and reduce the likelihood of fractures. For example, in June 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that osteoporosis was responsible for 2,659 deaths in 2022, which equates to 10.2 deaths per 100,000 people, accounting for 1.4% of all deaths. Thus, the rising prevalence of osteoporosis is propelling the growth of the osteoporosis drug market.
The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.
Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.
Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.
In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company that offers various pharmaceutical products, acquired EffRx Pharmaceuticals for an undisclosed amount. With this acquisition, Abiogen Pharma intends to bolster its international presence, enhance its product offerings in bone health, leverage synergies for more effective drug development, and concentrate on rare diseases. EffRx Pharmaceuticals, a Switzerland-based company, specializes in creating innovative treatments for osteoporosis, aiming to improve bone density and minimize fracture risk. Their therapies focus on specific biological pathways to promote bone health in patients suffering from this condition.
Major companies operating in the osteoporosis drugs market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Theramex, Radius Health Inc., Strides Pharma Science Limited, Apotex Inc.
North America was the largest region in the osteoporosis market in 2024. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Osteoporosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on osteoporosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for osteoporosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.